Skip to main content
EURAXESS

Cell and Oligonucleotide Therapy Fellowship with AstraZeneca (postdoc in the UK)

Details

Deadline
Research Field
Professions and applied sciences
Funding Type
Funding
Mobility Incoming
Career Stage
Established Researcher (R3) (Researchers who have developed a level of independence)
European Research Programme
Not funded by an EU programme

About

Outline

The Cell and Oligonucleotide Therapy Fellowship is funded by the Medical Research Council (MRC) with co-funding from AstraZeneca to support postdoctoral researchers in the UK working on cell and oligonucleotide therapy. The Fellowship is open to both clinical and non-clinical researchers. Applicants must have a PhD by the start of the fellowship and have the support of a research organization eligible for MRC funding. Letters of intent are due on January 28, 2022 and invited full applications are due on March 8, 2022.

What is funded

The Fellowship provides funding of up to 500,000 GBP.

Duration

3 years. 

Eligibility

Applications are open to early career researchers with a PhD of all nationalities and non-UK recipients of the award are eligible for a Global Talent visa.

Organisation

Organisation name
Medical Research Council (MRC)
Organisation Country
More Information
Disclaimer:

The responsibility for the funding offers published on this website, including the funding description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.